Matrix Metalloproteinase 14 promotes lung cancer by cleavage of Heparin-Binding EGF-like Growth Factor()()

Molecularly targeted therapies benefit approximately 15–20% of non-small cell lung cancer (NSCLC) patients carrying specific drug-sensitive mutations. Thus, there is a clinically unmet need for the identification of novel targets for drug development. Here, we performed RNA-deep sequencing to identi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neoplasia
Main Authors: Stawowczyk, Marcin, Wellenstein, Max D., Lee, Sharrell B., Yomtoubian, Shira, Durrans, Anna, Choi, Hyejin, Narula, Navneet, Altorki, Nasser K., Gao, Dingcheng, Mittal, Vivek
Formato: Artigo
Idioma:Inglês
Publicado: Neoplasia Press 2016
Assuntos:
Original article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5198728/
https://ncbi.nlm.nih.gov/pubmed/28013056
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2016.11.005
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares